Search

Search Constraints

You searched for: Author/Creator Cardiel, Mario H

Search Results

1. 199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. (April 2019)

2. 289 Comparison of ACR 1982/1997 and EULAR/ACR classification criteria for systemic lupus erythematosus in two multiethnic cohorts. (April 2019)

3. A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. (April 2021)

4. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Issue 10143 (21st July 2018)

5. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Issue 10381 (25th March 2023)

6. CE-19 Remission and low lupus disease activity status (LLDAS) protect lupus patients from damage occurrence: data from a multi-ethnic, multinational latin american lupus cohort. (31st August 2016)

7. CE-28 Antimalarials protects against thrombosis in patients with systemic lupus erythematosus (SLE): longitudinal data from a large latin american cohort. (31st August 2016)

8. CE-45 Baseline factors predictive of the occurrence of neuropsychiatric damage accrual in latin american patients with systemic lupus erythematosus. (31st August 2016)

9. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. (August 2020)

10. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. (August 2020)